miR-183-5p Is a Potential Molecular Marker of Systemic Lupus Erythematosus

Abstract

Objective. To investigate microRNA (miRNA) expression profiles in individuals with systemic lupus erythematosus (SLE) and identify the valuable miRNA biomarkers in diagnosing and monitoring SLE. Methods. Next-generation sequencing (NGS) was performed to assess miRNA amounts in peripheral blood mononuclear cells (PBMCs) from four SLE cases and four healthy controls. Quantitative polymerase chain reaction (qPCR) was carried out for validating candidate miRNAs in 32 SLE cases and 32 healthy controls. In addition, receiver operating characteristic (ROC) curve analysis was completed to evaluate diagnostic performance. Finally, the associations of candidate miRNAs with various characteristics of SLE were analyzed. Results. A total of 157 miRNAs were upregulated, and 110 miRNAs were downregulated in PBMCs from SLE cases in comparison to healthy controls, of which the increase of miR-183-5p and decrease of miR-374b-3p were validated by qPCR and both showed good diagnostic performance for SLE diagnosis. Besides, miR-183-5p expression levels displayed a positive association with SLE disease activity index (SLEDAI) and anti-dsDNA antibody amounts. Conclusion. Our data indicated that miR-183-5p is a promising biomarker of SLE.

Novel insight into miRNA biology and its role in the pathogenesis of systemic lupus erythematosus

“…A single-center study found that exosomal miR-146a expression was significantly downregulated and negatively correlated with anti-dsDNA antibody levels and ESR in SLE patients; Conversely, miR-21 and miR-155 were significantly elevated and positively correlated with proteinuria, which indicated that they may serve as potential biomarkers for the development of LN (95). The level of miR-183-5p expression in the PBMCs of SLE patients was positively correlated with SLEDAI-2000 and the amount of anti-dsDNA antibody by negatively regulating transcription factor (Foxo1) expression, which can be used as SLE biomarkers (96). Also, several miRNAs (miR-485-5p, miR-132, miR-145, and miR-183) have been suggested as promising SLE biomarkers (97)(98)(99).…”

Progress in the application of body fluid and tissue level mRNAs-non-coding RNAs for the early diagnosis and prognostic evaluation of systemic lupus erythematosus

“…The expression of miR-146a, miR-155, miR-371b-5p, and miR-5100 is increased in the peripheral blood of SLE patients (65, 66). The expression level of miR-183-5p is positively correlated with SLEDAI scores and the amount of anti-dsDNA antibodies (67). Serum hsa-miR-766-3p regulates the PI3K-AKT-mTOR pathway in SLE patients and participates in kidney injury (68).…”

Upregulation of microRNA‐762 suppresses the expression of GIPC3 in systemic lupus erythematosus and neuropsychiatric systemic lupus erythematosus

“…[1][2][3] Although the underling molecular mechanisms of SLE are still not fully clarified, the autologous nucleic acids are attacked by immune responses in SLE patients resulting from multiple genetic and environmental factors. 4,5 Meanwhile, the accumulation of overproduced autoantibodies would lead to the injury of various organs, such as kidney, skin, heart, and lungs. 6 Accordingly, the mortality rate of SLE patients is almost three times higher than healthy individuals, and the rate will increase as the disease progression.…”

“…Systemic lupus erythematosus (SLE) is a complex chronic, inflammatory systemic autoimmune disease involving innate and adaptive immune responses, usually characterized by flare, variable course, and multiple organ dysfunction 1–3 . Although the underling molecular mechanisms of SLE are still not fully clarified, the autologous nucleic acids are attacked by immune responses in SLE patients resulting from multiple genetic and environmental factors 4,5 . Meanwhile, the accumulation of overproduced autoantibodies would lead to the injury of various organs, such as kidney, skin, heart, and lungs 6 .…”